These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 28421789)
21. Potential of coconut oil and medium chain triglycerides in the prevention and treatment of Alzheimer's disease. Chatterjee P; Fernando M; Fernando B; Dias CB; Shah T; Silva R; Williams S; Pedrini S; Hillebrandt H; Goozee K; Barin E; Sohrabi HR; Garg M; Cunnane S; Martins RN Mech Ageing Dev; 2020 Mar; 186():111209. PubMed ID: 31953123 [TBL] [Abstract][Full Text] [Related]
22. Donepezil provides greater benefits in mild compared to moderate Alzheimer's disease: implications for early diagnosis and treatment. Molinuevo JL; Berthier ML; Rami L Arch Gerontol Geriatr; 2011; 52(1):18-22. PubMed ID: 19948364 [TBL] [Abstract][Full Text] [Related]
23. Trajectories of cognitive decline in different types of dementia. Smits LL; van Harten AC; Pijnenburg YA; Koedam EL; Bouwman FH; Sistermans N; Reuling IE; Prins ND; Lemstra AW; Scheltens P; van der Flier WM Psychol Med; 2015 Apr; 45(5):1051-9. PubMed ID: 25229325 [TBL] [Abstract][Full Text] [Related]
24. A Brief Review of Caprylidene (Axona) and Coconut Oil as Alternative Fuels in the Fight Against Alzheimer's Disease. Chintapenta M; Spence J; Kwon HI; Blaszczyk AT Consult Pharm; 2017 Dec; 32(12):748-751. PubMed ID: 29467067 [TBL] [Abstract][Full Text] [Related]
25. Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers. Stonnington CM; Snyder PJ; Hentz JG; Reiman EM; Caselli RJ J Clin Psychiatry; 2009 Oct; 70(10):1379-84. PubMed ID: 19573495 [TBL] [Abstract][Full Text] [Related]
26. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Mecocci P; Bladström A; Stender K Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640 [TBL] [Abstract][Full Text] [Related]
27. Efficacy of increasing donepezil in mild to moderate Alzheimer's disease patients who show a diminished response to 5 mg donepezil: a preliminary study. Yatabe Y; Hashimoto M; Kaneda K; Honda K; Ogawa Y; Yuuki S; Ikeda M Psychogeriatrics; 2013 Jun; 13(2):88-93. PubMed ID: 23909965 [TBL] [Abstract][Full Text] [Related]
28. Effectiveness of a community-based multidomain cognitive intervention program in patients with Alzheimer's disease. Kim HJ; Yang Y; Oh JG; Oh S; Choi H; Kim KH; Kim SH Geriatr Gerontol Int; 2016 Feb; 16(2):191-9. PubMed ID: 25656505 [TBL] [Abstract][Full Text] [Related]
29. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease. Bitner RS; Bunnelle WH; Decker MW; Drescher KU; Kohlhaas KL; Markosyan S; Marsh KC; Nikkel AL; Browman K; Radek R; Anderson DJ; Buccafusco J; Gopalakrishnan M J Pharmacol Exp Ther; 2010 Sep; 334(3):875-86. PubMed ID: 20504913 [TBL] [Abstract][Full Text] [Related]
30. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. Filip V; Kolibás E J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658 [TBL] [Abstract][Full Text] [Related]
31. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response. Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450 [TBL] [Abstract][Full Text] [Related]
34. Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition. Geerlings MI; Jonker C; Bouter LM; Adèr HJ; Schmand B Am J Psychiatry; 1999 Apr; 156(4):531-7. PubMed ID: 10200730 [TBL] [Abstract][Full Text] [Related]
35. Transcranial direct current stimulation as a memory enhancer in patients with Alzheimer's disease: a randomized, placebo-controlled trial. Bystad M; Grønli O; Rasmussen ID; Gundersen N; Nordvang L; Wang-Iversen H; Aslaksen PM Alzheimers Res Ther; 2016 Mar; 8(1):13. PubMed ID: 27005937 [TBL] [Abstract][Full Text] [Related]
37. No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia. Rainer M; Kraxberger E; Haushofer M; Mucke HA; Jellinger KA J Neural Transm (Vienna); 2000; 107(12):1475-81. PubMed ID: 11459000 [TBL] [Abstract][Full Text] [Related]
38. More Delusions May Be Observed in Low-Proficient Multilingual Alzheimer's Disease Patients. Liu YC; Liu YY; Yip PK; Akanuma K; Meguro K PLoS One; 2015; 10(11):e0140714. PubMed ID: 26554588 [TBL] [Abstract][Full Text] [Related]
39. Changes over time in memory, processing speed and clock drawing tests help to discriminate between vascular cognitive impairment, mild cognitive impairment and Alzheimer's disease. de Jager CA Neurol Res; 2004 Jul; 26(5):481-7. PubMed ID: 15362213 [TBL] [Abstract][Full Text] [Related]
40. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. Claxton A; Baker LD; Hanson A; Trittschuh EH; Cholerton B; Morgan A; Callaghan M; Arbuckle M; Behl C; Craft S J Alzheimers Dis; 2015; 44(3):897-906. PubMed ID: 25374101 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]